# Tolerance of PICC Line Versus Implanted Port for Adjuvant Chemotherapy in Early Breast Cancer

> **NCT02095743** · PHASE2 · UNKNOWN · sponsor: **Centre Henri Becquerel** · enrollment: 256 (estimated)

## Conditions studied

- Early Stage Breast Carcinoma

## Interventions

- **DEVICE:** implanted port for chemo administration (X-port isp)
- **DEVICE:** Use of a PICC line for chemo administration (PowerPICC SOLO²)

## Key facts

- **NCT ID:** NCT02095743
- **Lead sponsor:** Centre Henri Becquerel
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2014-04
- **Primary completion:** 2018-12
- **Final completion:** 2019-03
- **Target enrollment:** 256 (ESTIMATED)
- **Last updated:** 2018-07-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02095743

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02095743, "Tolerance of PICC Line Versus Implanted Port for Adjuvant Chemotherapy in Early Breast Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02095743. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*